Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07136857 · ClinicalTrials.gov registry record · Phase 2
Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)
A Phase 2 study of Glanzmann Thrombasthenia, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT07136857 is a Phase 2 study of Glanzmann Thrombasthenia that is actively recruiting participants, run by Emory University. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07136857, a Phase 2 study of Glanzmann Thrombasthenia, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is evaluating an investigational drug, eptacog beta (EB), for the treatment and prevention of acute bleeding episodes in people with Glanzmann Thrombasthenia, a rare inherited bleeding disorder. Eptacog beta (EB) is not currently approved by the U.S. Food and Drug Administration (FDA) for this condition. The study will assess the effectiveness and safety of eptacog beta (EB) when used to treat serious bleeding events, and in an optional phase, when used routinely to prevent bleeding. During the first three (3) months, participants will manage any bleeding episodes with their standard treatment (e.g., factor products or platelet transfusions). After this initial period, they will use the study drug to treat serious bleeding events. Participants will have approximately 4 to 5 visits with their hematologist over the 9-month study period. They will also be asked to complete a diary documenting bleeding episodes and treatments, and to answer questions about how bleeding affects their daily life. Blood samples will be collected to monitor their condition and any potential side effects of the study drug. At the end of the main study, participants will have the option to enter an optional extension phase, where they will receive routine intravenous infusions of the study drug 2 to 3 times per week for 6 months to help prevent future bleeding episodes and complications.
Conditions Studied
Interventions
- DRUG EPTACOG BETA
Study Locations (1)
Georgia
- Arthur M. Blank Hospital | Children's Healthcare of Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07136857
The ClinicalTrials.gov registry entry for NCT07136857 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glanzmann Thrombasthenia appearing as the primary indexed condition, and to 1 intervention - of which EPTACOG BETA is the first listed.
NCT07136857 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT07136857 about?
NCT07136857 is a clinical study titled "Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)". This study is evaluating an investigational drug, eptacog beta (EB), for the treatment and prevention of acute bleeding episodes in people with Glanzmann Thrombasthenia, a rare inherited bleeding disorder. Eptacog beta (EB) is not currently approved by the U.S. Food and Drug Administration (FDA) for...
What is the current status of trial NCT07136857?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2025-10-02. Estimated completion is 2026-12.
What conditions does trial NCT07136857 study?
This clinical trial studies the following conditions: Glanzmann Thrombasthenia.
What interventions are being tested in trial NCT07136857?
The interventions under investigation include: EPTACOG BETA (DRUG).
Who is sponsoring clinical trial NCT07136857?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07136857 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glanzmann Thrombasthenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
RECRUITING
-
A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.